| 1 | 47165-04-8 | 4',6-双脒基-2-苯基吲哚 | DAPI | C16H15N5
| | |
| 2 | 6295-84-7 | NSC49533 | NSC49533 | C16H15N5
| | |
| 3 | 406928-23-2 | AKOS BBS-00005564 | AKOS BBS-00005564 | C16H15N5
| | |
| 4 | | GLEEVEC INTERMEDIATE | GLEEVEC INTERMEDIATE | C16H15N5
| | |
| 5 | | 4',6-DIAMIDINO-2-PHENYLINDOL | 4',6-DIAMIDINO-2-PHENYLINDOL | C16H15N5
| | |
| 6 | | 4',6-DIAMIDINO-2-PHENYLINDOLE | 4',6-DIAMIDINO-2-PHENYLINDOLE | C16H15N5
| | |
| 7 | 7014-14-4 | 3-Cyano-1,5-di-p-tolylformazan, 90% | 3-Cyano-1,5-di-p-tolylformazan, 90% | C16H15N5
| | |
| 8 | 89505-04-4 | N,N'-双(2-苯并咪唑甲基)胺 | N,N'-Bis(2-benzimidazolylmethyl)amine | C16H15N5
| | |
| 9 | | BIS-(1-METHYL-1H-BENZOIMIDAZOL-2-YL)-AMINE | BIS-(1-METHYL-1H-BENZOIMIDAZOL-2-YL)-AMINE | C16H15N5
| | |
| 10 | 23521-13-3 | 5-[[p-(Dimethylamino)phenyl]azo]quinoxaline | 5-[[p-(Dimethylamino)phenyl]azo]quinoxaline | C16H15N5
| | |
| 11 | 693241-47-3 | 4-AMINO-2-BENZYLAMINO-6-PHENYL-1,3,5-TRIAZINE | 4-AMINO-2-BENZYLAMINO-6-PHENYL-1,3,5-TRIAZINE | C16H15N5
| | |
| 12 | 152460-10-1 | N-(5-氨基-2-甲基苯基)-4-(3-吡啶基)-2-氨基嘧啶 | 4-Methyl-3-[4-(3-pyridyl)pyrimidin-2-ylamino]aniline | C16H15N5
| 嘧啶;抗肿瘤;中间体;通用试剂;杂环砌块;医药中间体;抗肿瘤药物;伊马替尼杂质;伊马替尼中间体;对照品-杂质对照品 | 中间体 |
| 13 | 124570-60-1 | 5-piperidinopyrazolo[1,5-a]quinazoline-3-carbonitrile | 5-piperidinopyrazolo[1,5-a]quinazoline-3-carbonitrile | C16H15N5
| | |
| 14 | | N-1H-BENZIMIDAZOL-2-YL-1-ETHYL-1H-BENZIMIDAZOL-2-AMINE | N-1H-BENZIMIDAZOL-2-YL-1-ETHYL-1H-BENZIMIDAZOL-2-AMINE | C16H15N5
| | |
| 15 | | 1-Phenyl-2-ethylamino-1H-[1,2,4]triazolo[1,5-b]indazole | 1-Phenyl-2-ethylamino-1H-[1,2,4]triazolo[1,5-b]indazole | C16H15N5
| | |
| 16 | | 1,2'-DIMETHYL-1 H ,1' H-[2,5']BIBENZOIMIDAZOLYL-5-YLAMINE | 1,2'-DIMETHYL-1 H ,1' H-[2,5']BIBENZOIMIDAZOLYL-5-YLAMINE | C16H15N5
| | |
| 17 | | N-[(5-METHYLPYRAZIN-2-YL)METHYL]-5-PHENYLPYRIMIDIN-2-AMINE | N-[(5-METHYLPYRAZIN-2-YL)METHYL]-5-PHENYLPYRIMIDIN-2-AMINE | C16H15N5
| | |
| 18 | 81430-43-5 | [4-[(2-cyanoethyl)ethylamino]phenyl]ethylenetricarbonitrile | [4-[(2-cyanoethyl)ethylamino]phenyl]ethylenetricarbonitrile | C16H15N5
| | |
| 19 | 112696-91-0 | 伊马替尼杂质胺 | 2-METHYL-N1-[4-(3-PYRIDINYL)-2-PYRIMIDINYL]-1,4-BENZENEDIAMINE | C16H15N5
| 杂质;伊马替尼杂质 | 杂质;伊马替尼杂质;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals;Aromatics, Heterocycles, Metabolites & Impurities, Pharmaceuticals, Intermediates & Fine Chemic |
| 20 | 571187-03-6 | N-(3-氨基-4-甲基苯基)-4-(吡啶-3-基)-2-嘧啶-胺 | 1,3-Benzenediamine, 4-methyl-N1-[4-(3-pyridinyl)-2-pyrimidinyl] | C16H15N5
| | |
| 21 | 1352242-48-8 | 1,3-Benzenediamine, 2-methyl-N1-[4-(3-pyridinyl)-2-pyrimidinyl]- | 1,3-Benzenediamine, 2-methyl-N1-[4-(3-pyridinyl)-2-pyrimidinyl]- | C16H15N5
| | |
| 22 | | N-[4-(1H-1,2,3,4-tetrazol-1-yl)phenyl]-2,3-dihydro-1H-inden-1-amine | N-[4-(1H-1,2,3,4-tetrazol-1-yl)phenyl]-2,3-dihydro-1H-inden-1-amine | C16H15N5
| | |
| 23 | 1665196-22-4 | 4-(1-(2-(1-methyl-1H-pyrazol-4-yl)ethyl)-1H-imidazol-5-yl)benzonitrile | 4-(1-(2-(1-methyl-1H-pyrazol-4-yl)ethyl)-1H-imidazol-5-yl)benzonitrile | C16H15N5
| | |
| 24 | | (9-METHYL-9H-BENZO[4,5]IMIDAZO[2,1-C][1,2,4]TRIAZOL-3-YL)-P-TOLYL-AMINE | (9-METHYL-9H-BENZO[4,5]IMIDAZO[2,1-C][1,2,4]TRIAZOL-3-YL)-P-TOLYL-AMINE | C16H15N5
| | |
| 25 | | 1-(P-AMINOPHENYL)-3,3A-DIHYDRO-4-METHYL(1,2,4)TRIAZOLO(4,3-A)QUINOXALINE | 1-(P-AMINOPHENYL)-3,3A-DIHYDRO-4-METHYL(1,2,4)TRIAZOLO(4,3-A)QUINOXALINE | C16H15N5
| | |
| 26 | 1357349-91-7 | SPP-86 | 1-(1-Methylethyl)-3-(2-phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | C16H15N5
| | |
| 27 | | 4-{[(2-{[1,2,4]triazolo[3,4-a]pyridin-3-yl}ethyl)amino]methyl}benzonitrile | 4-{[(2-{[1,2,4]triazolo[3,4-a]pyridin-3-yl}ethyl)amino]methyl}benzonitrile | C16H15N5
| | |
| 28 | | 2,3-Dihydro-3-methyl-3-(4-pyridyl)-8-(1H-pyrrol-1-yl)-1,2,4-triazolo[4,3-a]pyridine | 2,3-Dihydro-3-methyl-3-(4-pyridyl)-8-(1H-pyrrol-1-yl)-1,2,4-triazolo[4,3-a]pyridine | C16H15N5
| | |